Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Ascletis Announces China IND Approval of Its Second FASN Inhibitor ASC60 for Treatment of Advanced Solid Tumors 2022-04-06 17:10
Ascletis Announces Completion of First Sale of Its Ritonavir Tablets in Zhejiang Province 2022-04-04 17:10
Ascletis Announces Submission of Marketing Authorization Application for Ritonavir in Hong Kong 2022-04-03 18:20
Ascletis Announces Completion of Patient Enrollment in Phase II Clinical Trial of ASC42, an In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication 2022-03-30 18:26
Ascletis Announces the Latest Results of the Preclinical Studies of Two Novel Anti-Cancer Drug Candidates, ASC61 and ASC60, to be presented at AACR Annual Meeting 2022 2022-03-27 18:30
Business Update on ASC10, an Oral Double Prodrug against COVID-19 2022-03-15 19:55
Ascletis Announces Further Expansion of Ritonavir Oral Tablet Production Capacity to 530 Million Tablets Per Year 2022-03-13 18:30
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Eight Additional European Countries 2022-03-01 17:30
Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients 2022-02-14 17:34
Ascletis Announces Submission of Marketing Authorization Applications for Ritonavir in Multiple European Countries 2022-02-13 18:30
Ascletis Announces Positive Data of Oral Double Prodrug ASC10 and Its Antiviral Nucleoside Analog ASC10-A Against Omicron Variant 2022-02-07 19:00
Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors 2022-02-06 18:30
Ascletis Announces IND Filing of Its Second FASN Inhibitor ASC60 for Advanced Solid Tumors Accepted by China NMPA 2022-01-26 19:00
Ascletis Announces First Patient Dosed in the Phase III Clinical Trial of FASN Inhibitor ASC40 Combined with Bevacizumab for Treatment of Recurrent Glioblastoma 2022-01-23 18:35
Ascletis Announces Signing of Ritonavir Tablet Purchase Agreement with Phokam Pharmaceutical Import-Export Co., Ltd of Laos 2022-01-18 18:00
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B 2022-01-17 18:12
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne 2022-01-13 17:30
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication 2022-01-11 08:30
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors 2022-01-10 08:30
Gannex Announces Completion of the U.S. Phase I Trial of ASC43F, an In-House Developed First-in-Class Dual Targeting Fixed-dose Combination Tablet for NASH 2022-01-04 08:30
1 2 3 4 5 6 8